A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo! Finance) implies a significant 131% upside from its current levels. And ...

“And it’s all stuff we actually want to know, so it sticks in your brain. Like when I hear someone talk about CRISPR (gene ...

Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...

The surge in genetic disorders such as cystic fibrosis ... Food and Beverage, Consumer Technology, Healthcare, Industrial, ...